Bispecific antibody and bivalent hapten radioimmunotherapy in CEA- producing medullary thyroid cancer xenograft

Journal of Nuclear Medicine

Volumn 40, Issue 1, 1999, Pages 198-204

  Kraeber Bodéré, Françoise ^a   Faivre Chauvet, Alain ^b   Saï Maurel, Catherine ^b   Gautherot, Emmanuel ^b   Fiche, Maryse ^b   Campion, Loïc ^b   Le Boterff, Jean ^b   Barbet, Jacques ^b   Chatal, Jean François ^b   Thédrez, Philippe ^b  

^a INSTITUT DE BIOLOGIE   (France)

^b NONE

Author keywords

Bispecific antibody; Medullary thyroid cancer; Radioimmunotherapy; Two step targeting

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; HAPTEN;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THYROID CANCER; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; HAPTENS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PENTETIC ACID; RADIOIMMUNOTHERAPY; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032898058     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
2. Mach JP, Pèlegrin A, Buchegger F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol. 1991;3:685-693.
3. Chatal JF, Mahé M. Therapeutic use of radiolabeled antibodies. In: Murray P. Ell P, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Scotland: Churchill Livingston; 1998:1101-1114.
4. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
5. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 1990;50:3445-3452.
6. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid. 1995;5:407-424.
7. Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer. 1976;34:111-115.
8. Peltier P, Curtet C, Chatal JF, et al. Radioimmunodelection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-111-labeled DTPA Dimer. J Nucl Med. 1993;34:1267-1273.
9. Bardiès M, Bardet S, Faivre A, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med. 1996;37:1853-1859.
10. Hosono M, Hosono M, Kraeber-Bodéré F, et al. Two-step targeting of medullary thyroid cancer with bispecific antibody and iodine-125-labeled DTPA-indium bivalent hapten in mice. J Nucl Med. 1998;39:1608-1613.
11. Gautherot E, Le Doussal JM, Bouhou J, et al. Delivery of therapeutic doses of radio-iodine using bispecific antibody-targeted bivalent haptens. J Nucl Med. 1998;39:1937-1943.
12. Accolla RS, Carrel S, Mach JP. Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines. Proc Nat Acad Sci USA. 1980;77:563-566.
13. Farker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramine: 1,3,4,6 tetrachloro-3a, 6a-diphenyl glycoluryl. Biophys Res Commun. 1978;80:849-854.
14. Hosono M, Endo K, Hosono M, et al. Treatment of small-cell lung cancer xenografts with iodine-131-anti-neural cell adhesion molecule monoclonal antibody and evaluation of absorbed dose in tissue. J Nucl Med. 1994;34:269-300.
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of cell proliferation analysis-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;33:1710-1715.
16. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med. 1990;31:1035-1044.
17. Axworthy D, Fritzberg A, Hylarides MD, et al. Durable complete regressions of breast, lung and colon tumor xenografts with a single dose of pretargeted Y-90 in a mouse model [abstract]. J Nucl Med. 1995;36:217P.
18. Klein J, Nguyen TH, Laroque P, et al. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma. Cancer Res. 1989;49:6383-6389.
19. Devys A, Thédrez P, Gautherot E, et al. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. Int J Cancer. 1996;67:883-891.
20. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997;57:447-453.
21. Gautherot E, Bouhou J, Loucif E, et al. Radioimmunotherapy of LS174T colon carcinoma-grafted mice using an iodine-131-labeled bivalent hapten combined with an anti-CEA × anti-indium-DTPA bispecific antibody [abstract]. Tumor Target. 1996;3:151.
22. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimrnunotherapy. J Natl Cancer Inst. 1990;82: 763-771.
23. 131I-labeled anti-CEA antibodies. J Nucl Med. 1996;37:905-911.
24. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat Res. 1992;132:351-358.